These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 33763759)
1. Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat. Italiya KS; Singh AK; Chitkara D; Mittal A AAPS PharmSciTech; 2021 Mar; 22(3):114. PubMed ID: 33763759 [TBL] [Abstract][Full Text] [Related]
2. Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. Italiya KS; Basak M; Mazumdar S; Sahel DK; Shrivastava R; Chitkara D; Mittal A Mol Pharm; 2019 Dec; 16(12):4954-4967. PubMed ID: 31647676 [TBL] [Abstract][Full Text] [Related]
3. Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. Italiya KS; Mazumdar S; Sharma S; Chitkara D; Mahato RI; Mittal A Nanomedicine; 2019 Jan; 15(1):175-187. PubMed ID: 30300750 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. Italiya KS; Sharma S; Kothari I; Chitkara D; Mittal A J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():49-56. PubMed ID: 28704725 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice. Wyska E; Szymura-Oleksiak J; Pekala E; Obruśnik A J Pharm Pharmacol; 2007 Apr; 59(4):495-501. PubMed ID: 17430632 [TBL] [Abstract][Full Text] [Related]
6. Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. Wyska E; Świerczek A; Pociecha K; Przejczowska-Pomierny K Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):403-12. PubMed ID: 25663650 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes. Cui P; Macdonald TL; Chen M; Nadler JL Bioorg Med Chem Lett; 2006 Jul; 16(13):3401-5. PubMed ID: 16650991 [TBL] [Abstract][Full Text] [Related]
8. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. Striffler JS; Nadler JL Metabolism; 2004 Mar; 53(3):290-6. PubMed ID: 15015139 [TBL] [Abstract][Full Text] [Related]
9. Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans. Świerczek A; Wyska E; Pociecha K; Baś S; Mlynarski J Xenobiotica; 2019 Oct; 49(10):1209-1220. PubMed ID: 30526201 [TBL] [Abstract][Full Text] [Related]
10. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. Zakeri-Milani P; Valizadeh H; Tajerzadeh H; Azarmi Y; Islambolchilar Z; Barzegar S; Barzegar-Jalali M J Pharm Pharm Sci; 2007; 10(3):368-79. PubMed ID: 17727800 [TBL] [Abstract][Full Text] [Related]
11. Restoring physiological parameters of the pancreas and kidney through treatment with a polymeric nano-formulation of C-peptide and lisofylline combination in diabetic nephropathy. Singh AK; Sai Pradyuth K; Chitkara D; Mittal A Nanoscale; 2024 Aug; 16(34):16058-16074. PubMed ID: 39082128 [TBL] [Abstract][Full Text] [Related]
12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
13. Lisofylline: a potential lead for the treatment of diabetes. Yang Z; Chen M; Nadler JL Biochem Pharmacol; 2005 Jan; 69(1):1-5. PubMed ID: 15588708 [TBL] [Abstract][Full Text] [Related]
14. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Yang Z; Chen M; Ellett JD; Fialkow LB; Carter JD; Nadler JL Transplantation; 2004 Jan; 77(1):55-60. PubMed ID: 14724435 [TBL] [Abstract][Full Text] [Related]
15. Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. Bursten SL; Federighi D; Wald J; Meengs B; Spickler W; Nudelman E J Pharmacol Exp Ther; 1998 Jan; 284(1):337-45. PubMed ID: 9435196 [TBL] [Abstract][Full Text] [Related]
16. Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Chen M; Yang Z; Wu R; Nadler JL Endocrinology; 2002 Jun; 143(6):2341-8. PubMed ID: 12021199 [TBL] [Abstract][Full Text] [Related]
17. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700 [TBL] [Abstract][Full Text] [Related]
18. Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats. Wattanasirichaigoon S; Menconi MJ; Fink MP Crit Care Med; 2000 May; 28(5):1540-9. PubMed ID: 10834709 [TBL] [Abstract][Full Text] [Related]